Dr. Xingli Wang

But from last year, we have done a major shake-up of the new drug development.

And we reduced a bit of efforts on the generic drug development, but shifted most of our resource onto the innovative medicine side by focusing on oncology.

continuously.

At the same time, we put a lot more emphasis on the autoimmune disease as well as the degenerative, you know, neurodegenerative disease like the Alzheimer's and Parkinson's.

And at the same time, we also pay attention to metabolic aspect, including GLP-1.

We're also looking into the, you know, the small molecule for oral formulation and also the cardiovascular in relation to the SRNA aspect.

So it's a

I focused the strategy with coordinated portfolio technical modality platform among different entities of the Fusong Pharma, either in the headquarter as well as the subsidiaries of the different companies, and by moving towards the larger

I would say, high-value drugs, as well as the global reach towards the U.S.

and the European markets.

And including where we are might be slightly different from other, especially big, farmers.

We're looking also into Middle Eastern countries as well as Southeastern Asian countries of expanding our global reach and business.

You have a lot of questions buried within one question.

I will try to address it a little bit.

Our grand scheme of having so many subsidiaries, we have a lot of subsidiaries, is really because of our ability or competence at the time when we started drug development business, we were not experienced.

We did not have much knowledge, expertise in the novel medicine drug development.

So in the way we starting small, by starting small, the best way to do that is to start up a biotech as subsidiary companies with a focus on one technical platform.

That's how we started the Henleus.

So we start with also in more of low risk environment, we start with the biosimilars.

As you know, the highest risk when you develop a new drug is developed on a target which has never been developed because you don't know what outcome is.